Table 6.
The interaction between gene promoter region methylation and different cancer stages for 5-year OS of CRC patients.
| Normal tissues | Tumor tissues | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of subjects | No. of cases (%) | Crude | Adjusted | No. of subjects | No. of cases (%) | Crude | Adjusted | |||||
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |||||
| ≧2 of genes | ||||||||||||
| UnMe/local (1&2) | 36 | 6 (16.7) | 1.00 | Referent | 1.00 | Referent | 20 | 4 (20.0) | 1.00 | Referent | 1.00 | Referent |
| UnMe/advanced (3&4) | 31 | 8 (25.8) | 1.73 | (0.60 to 5.00) | 4.69 | (0.98 to 22.5) | 8 | 2 (25.0) | 1.06 | (0.20 to 5.81) | 4.74 | (0.42 to 53.2) |
| Me/local (1&2) | 41 | 7 (17.1) | 1.15 | (0.39 to 3.41) | 1.23 | (0.22 to 6.91) | 57 | 9 (15.8) | 0.82 | (0.25 to 2.66) | 1.23 | (0.14 to 10.9) |
| Me/advanced (3&4) | 45 | 10 (22.2) | 1.74 | (0.63 to 4.79) | 3.97 | (0.83 to 19.1) | 68 | 16 (23.5) | 1.46 | (0.49 to 4.38) | 4.42 | (0.57 to 34.5) |
| p for trend | 0.44 | 0.31 | 0.40 | 0.10 | ||||||||
Abbreviations: OS, overall survival; CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval.
Adjusted for gender, age at surgery (continuous), adjuvant chemotherapy, histological grade and tumor location.
UnMe/loccal (1&2): DNA promoter region unmethylated with cancer stage 1 or 2.
UnMe/advanced (3&4): DNA promoter region unmethylated with cancer stage 3 or 4.
Me/local (1&2): DNA promoter region methylated with cancer stage 1 or 2.
Me/advanced (3&4): DNA promoter region methylated with cancer stage 3 or 4.